HealthExec June 6, 2024
Chad Van Alstin

The U.S. Food and Drug Administration (FDA) has agreed in a unanimous vote to recommend an update of the formula for the COVID-19 vaccine in time for the annual booster campaign this fall.

The new formula is aimed at curbing the JN.1 variant of the virus, which the FDA’s committee of independent advisors said is causing the majority of infections. Officially, the decision by the FDA is a request to drug manufacturers to change course—that is, if the recommendation is approved.

The committee’s recommendation now moves up the ladder at the FDA for approval. What’s new in this scenario is the booster formula would be monovalent, to counter the JN.1 variant specifically. Previous iterations of COVID-19 boosters have...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Healthcare System, Patient / Consumer, Pharma / Biotech, Provider, Public Health / COVID
Related Articles:
FDA warns GLP-1 compounder over safety rules
GLP-1 drug approvals: A breakdown
Rethinking FDA’s Accelerated Approval Pathway: New Draft Guidances and Implications for Drug Companies
FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use
Certainty vs. speed: How do patients feel about the tradeoff for new cancer drugs?

Share This Article